Q3 SPARC DELETION MUTANT AND USES THEREOF
The invention provides for SPARC polypeptides with a mutation corresponding to a deletion of the third glutamine in the mature fault of the human SPARC protein, nucleic acids encoding such polypeptides, antibodies against such polypeptides, and methods of the use of such polypeptides, nucleic acids, and antibodies.
1 - 64 . (canceled)
65 . A method of treating a disease in a mammal comprising administering a SPARC polypeptide comprising SEQ ID NO: 1 to the mammal.
66 . The method of claim 65 , further comprising administering one or more additional therapeutic agents.
67 . The method of claim 66 , wherein the one or more additional therapeutic agents are selected from the group consisting of therapeutic radionuclides, adriamycin, ansamycin, antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, 5-fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin and derivatives, mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, anti-vascular endothelial growth factor compounds, anti-epidermal growth factor receptor compounds, tyrosine kinase inhibitors, and biologically active agents.
68 . The method of claim 67 , wherein the additional therapeutic agent is 5-fluorouracil.
69 . The method of claim 66 , wherein the additional therapeutic agent is comprised of paclitaxel albumin nanoparticles.
70 . The method of claim 65 , further comprising the administration of one or more angiogenesis inhibitors.
71 . The method of claim 65 , wherein the disease is a cell proliferative disease.
72 . The method of claim 71 , wherein the cell proliferative disease is a cancer.
73 . The method of claim 72 , wherein the cancer is selected from the group consisting cancer of the brain, oral cavity and pharynx, esophagus, stomach, small intestine, colon, rectum, anus, liver, gall bladder, pancreas, larynx, lung, bronchus, uterine cervix, uterine corpus, ovary vulva, vagina, prostate, testis, and penis, genital systems, urinary bladder, kidney, renal pelvis, ureter, sarcomas, meningioma, Hodgkin's disease, Non-Hodgkin's lymphoma, multiple myeloma, and leukemia.
74 . The method of claim 65 , wherein the mammal is a human.
75 . A method of treating a disease in a mammal comprising administering a SPARC polypeptide comprising SEQ ID NO: 2 to the mammal.
76 . The method of claim 75 , further comprising administering one or more additional therapeutic agents.
77 . The method of claim 76 , wherein the one or more additional therapeutic agents are selected from the group consisting of therapeutic radionuclides, adriamycin, ansamycin, antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, 5-fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin and derivatives, mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, anti-vascular endothelial growth factor compounds, anti-epidermal growth factor receptor compounds, tyrosine kinase inhibitors, and biologically active agents.
78 . The method of claim 77 , wherein the additional therapeutic agent is 5-fluorouracil.
79 . The method of claim 76 , wherein the additional therapeutic agent is comprised of paclitaxel albumin nanoparticles.
80 . The method of claim 75 , further comprising the administration of one or more angiogenesis inhibitors.
81 . The method of claim 75 , wherein the disease is a cell proliferative disease.
82 . The method of claim 81 , wherein the cell proliferative disease is a cancer.
83 . The method of claim 82 , wherein the cancer is selected from the group consisting cancer of the brain, oral cavity and pharynx, esophagus, stomach, small intestine, colon, rectum, anus, liver, gall bladder, pancreas, larynx, lung, bronchus, uterine cervix, uterine corpus, ovary vulva, vagina, prostate, testis, and penis, genital systems, urinary bladder, kidney, renal pelvis, ureter, sarcomas, meningioma, Hodgkin's disease, Non-Hodgkin's lymphoma, multiple myeloma, and leukemia.
84 . The method of claim 75 , wherein the mammal is a human.